XNAS · Healthcare · Biotechnology
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.38 | -0.48 | -26.32% | $0 | ❌ Miss | -1.04% | +1.49% | — |
| 2026-05-11 | Q1 2026 | -0.40 | -0.50 | -25.00% | $0 | ❌ Miss | +0.00% | -8.79% | -25.27% |
| 2026-03-30 |
| Q4 2025 |
| -0.43 |
| -0.37 |
| +13.95% |
| $0 |
| ✅ Beat |
| +0.48% |
| +7.74% |
| +8.55% |
| 2025-11-13 | Q3 2025 | -0.46 | -0.40 | +13.04% | $0 | ✅ Beat | — | — | — |
| 2025-08-13 | Q2 2025 | -0.49 | -0.47 | +4.08% | $0 | ✅ Beat | +0.86% | -11.89% | -14.52% |
| 2025-03-24 | Q4 2024 | -0.43 | -0.52 | -20.93% | $0 | ❌ Miss | +1.14% | -16.29% | -17.71% |
| 2024-03-27 | Q4 2023 | -1.82 | -0.50 | +72.53% | $0 | ✅ Beat | — | — | — |
| 2023-05-11 | Q1 2023 | -0.54 | -0.46 | +14.81% | $0 | ✅ Beat | +0.39% | +16.36% | +22.53% |
Showing last 8 quarters.